Market Report: Taking Stock
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The blood shortage is directing attention towards Haemocell, which has developed a blood filtration system that, in effect, does away with the need for many blood transfusions.
The struggling healthcare group, up 0.25p to 3.5p, has had a wounding time, running into financial difficulties and hit by a series of marketing problems. Three years ago the shares were 182p. Haemocell believes it needs a little help to grow. It is involved in talks which could lead to a reverse takeover.
John Lusty, the acquisitive niche food group, continues to seek acquisitions and is likely to clinch a deal soon. Interim profits rose 159 per cent to pounds 609,000 and year's profits should be around pounds 1.9m against pounds 753,000. The shares edged ahead 0.25p to 9p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments